"Wayne Patterson has appointed Public Relations Mr. Simon Buckingham as Non-Executive Director and I would like to also thank Mr. Michael Bennett for his twelve years of commitment to the company."
Wayne Paterson has recently made two appointments, Bob Pickard and Simon Buckingham, both remarkable individuals,
Bob Pickard
Admedus Limited (Admedus) today announced that Signal Leadership Communication Inc. (Signal) of Toronto has been appointed as its new public relations firm. Signal Principal Bob Pickard will personally serve as corporate communication counsel for Admedus.
“Bob is one of the public relations world’s best known and most respected leaders,” says Admedus Chairman and Interim CEO Wayne Paterson. “We look forward to applying his 25 years of experience in international communication which he has gained working in the United States, Japan, Korea, Singapore and his native Canada. Admedus is advancing on many fronts and now we need to take our global communication to the next level so that people know all about the promising progress we are making.”
“Admedus has a significant story to share and Signal is honored to earn the company’s confidence as corporate communication consultancy,” says Pickard. “In the PR trade, there is nothing better for client business success than working with strong leaders who understand the importance of communication. Wayne was an exceptional client of mine in Tokyo a few years ago when he ran a hypergrowth business in Japan and I am excited to serve under his distinguished leadership again working with the talented Admedus team.”
Simon Buckingham
The Company further announced the appointment of Mr. Simon Buckingham to its Board of Directors as a Non-Executive Director.
Mr. Buckingham has more than 25 years’ experience in the global pharmaceutical industry across a range of functions and a variety of therapeutic areas. Now based in Sydney, Mr. Buckingham is currently a senior global advisor to Actelion, one of the world’s leading biopharmaceutical companies, and is a director of Actelion Australia. He was President, Global Corporate and Business Development at Actelion from 2005-2011, a position which spanned licensing, M&A, alliance management and corporate strategic planning. Mr. Buckingham served as President, North America and Asia-Pacific at Actelion from 2000-2005, with responsibility for all commercial operations in the region. He was the founding President of Actelion Pharmaceuticals US. From 1998-2000 he worked in sales and marketing for Parke-Davis (now part of Pfizer) in the US and prior to that served at Roche, both in Switzerland and Australia.
Mr. Buckingham is currently a non-executive director of: Pharmaxis Ltd (ASX), an Australian pharmaceutical research company with a portfolio including two respiratory products approved in various world markets and a research pipeline focused on areas of high unmet clinical need in inflammatory and fibrotic diseases; Creso Pharma Ltd (ASX), specialising in cannabis derived pharmaceutical-grade nutriceutical products for human and animal health; Vaxxilon AG, a European based start-up, founded by the Max Planck Society and Actelion, dedicated to the discovery, development and commercialisation of innovative synthetic carbohydrate vaccines; and the Can Too Foundation, a non-profit organisation promoting health and wellbeing while raising funds for cancer research.
Mr. Buckingham holds a Bachelor of Veterinary Science degree from the University of Sydney, a PhD from the University of Melbourne, a Graduate Management Qualification from the AGSM, University of NSW and is a Graduate of the Australian Institute of Company Directors.
“Simon Buckingham brings to Admedus an extremely impressive depth of experience and a full spectrum of the most relevant qualifications. The Board welcomes him to Admedus and looks forward to his insight and contribution as we continue the Company’s progress with growth and expansion”, said Mr. Paterson.
AHZ Price at posting:
32.0¢ Sentiment: Buy Disclosure: Held
(20min delay)